MX385085B - Uso de beta-agonistas del receptor de la hormona tiroidea. - Google Patents
Uso de beta-agonistas del receptor de la hormona tiroidea.Info
- Publication number
- MX385085B MX385085B MX2018012900A MX2018012900A MX385085B MX 385085 B MX385085 B MX 385085B MX 2018012900 A MX2018012900 A MX 2018012900A MX 2018012900 A MX2018012900 A MX 2018012900A MX 385085 B MX385085 B MX 385085B
- Authority
- MX
- Mexico
- Prior art keywords
- agonists
- hormone receptor
- thyroid hormone
- receptor beta
- beta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326436P | 2016-04-22 | 2016-04-22 | |
| PCT/US2017/029120 WO2017185087A1 (en) | 2016-04-22 | 2017-04-24 | Use of thyroid beta-agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012900A MX2018012900A (es) | 2019-07-01 |
| MX385085B true MX385085B (es) | 2025-03-14 |
Family
ID=60116400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012900A MX385085B (es) | 2016-04-22 | 2017-04-24 | Uso de beta-agonistas del receptor de la hormona tiroidea. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11351183B2 (enExample) |
| EP (1) | EP3445373B1 (enExample) |
| JP (1) | JP6931042B2 (enExample) |
| KR (1) | KR102407059B1 (enExample) |
| AU (1) | AU2017252126B2 (enExample) |
| BR (1) | BR112018071586A2 (enExample) |
| CA (1) | CA3021681C (enExample) |
| ES (1) | ES2992773T3 (enExample) |
| MX (1) | MX385085B (enExample) |
| WO (1) | WO2017185087A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2992773T3 (en) | 2016-04-22 | 2024-12-18 | Viking Therapeutics Inc | Use of thyroid beta-agonists |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| CA2543132A1 (en) | 2003-10-23 | 2005-05-19 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| CA2546601A1 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| SG144145A1 (en) | 2004-12-08 | 2008-07-29 | Sirion Therapeutics Inc | Methods, assays and compositions for treating retinol-related diseases |
| US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| RU2007148927A (ru) * | 2005-05-26 | 2009-07-10 | Метабэйзис Терапьютикс, Инк. (Us) | Новые тиреомиметики, содержащие фосфиновую кислоту |
| US20090042857A1 (en) | 2006-02-20 | 2009-02-12 | Masuo Yamaoka | Novel Pharmaceutical |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| MX344807B (es) | 2011-06-21 | 2017-01-09 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3). |
| JP2016517883A (ja) | 2013-05-03 | 2016-06-20 | オレゴン ヘルス アンド サイエンス ユニバーシティー | Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
| JP2018510849A (ja) | 2015-02-20 | 2018-04-19 | オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ | ソベチロムの誘導体 |
| JP6862459B2 (ja) | 2016-02-29 | 2021-04-21 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | ヒンジリッド容器およびブランク |
| KR102407053B1 (ko) | 2016-04-22 | 2022-06-10 | 바이킹 테라퓨틱스 인코포레이티드 | 갑상선 베타-작용제의 사용 |
| ES2992773T3 (en) | 2016-04-22 | 2024-12-18 | Viking Therapeutics Inc | Use of thyroid beta-agonists |
| KR102331596B1 (ko) | 2016-05-18 | 2021-11-25 | 오레곤 헬스 앤드 사이언스 유니버시티 | 소베티롬의 유도체 |
-
2017
- 2017-04-24 ES ES17786798T patent/ES2992773T3/es active Active
- 2017-04-24 EP EP17786798.3A patent/EP3445373B1/en active Active
- 2017-04-24 JP JP2019507069A patent/JP6931042B2/ja active Active
- 2017-04-24 AU AU2017252126A patent/AU2017252126B2/en active Active
- 2017-04-24 WO PCT/US2017/029120 patent/WO2017185087A1/en not_active Ceased
- 2017-04-24 MX MX2018012900A patent/MX385085B/es unknown
- 2017-04-24 US US16/095,228 patent/US11351183B2/en active Active
- 2017-04-24 BR BR112018071586-7A patent/BR112018071586A2/pt not_active Application Discontinuation
- 2017-04-24 KR KR1020187033713A patent/KR102407059B1/ko active Active
- 2017-04-24 CA CA3021681A patent/CA3021681C/en active Active
-
2022
- 2022-05-06 US US17/738,621 patent/US11951114B2/en active Active
-
2024
- 2024-03-05 US US18/595,919 patent/US12440502B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3021681A1 (en) | 2017-10-26 |
| EP3445373A4 (en) | 2019-12-18 |
| JP2019515033A (ja) | 2019-06-06 |
| US12440502B2 (en) | 2025-10-14 |
| CA3021681C (en) | 2024-09-24 |
| KR102407059B1 (ko) | 2022-06-10 |
| EP3445373A1 (en) | 2019-02-27 |
| WO2017185087A1 (en) | 2017-10-26 |
| ES2992773T3 (en) | 2024-12-18 |
| US20220257618A1 (en) | 2022-08-18 |
| US11951114B2 (en) | 2024-04-09 |
| AU2017252126A1 (en) | 2018-11-08 |
| JP6931042B2 (ja) | 2021-09-01 |
| MX2018012900A (es) | 2019-07-01 |
| BR112018071586A2 (pt) | 2019-02-12 |
| US20250000880A1 (en) | 2025-01-02 |
| AU2017252126B2 (en) | 2023-02-09 |
| US20190321379A1 (en) | 2019-10-24 |
| US11351183B2 (en) | 2022-06-07 |
| KR20190039027A (ko) | 2019-04-10 |
| EP3445373B1 (en) | 2024-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17063327A (es) | Receptores de antígeno quiméricos antidll3 y métodos de uso | |
| MX374788B (es) | Anticuerpos anti-tim3 y metodos de uso. | |
| ECSP18094857A (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
| MX386587B (es) | ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO. | |
| CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
| CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| EA201791117A1 (ru) | Частичные агонисты инсулинового рецептора | |
| EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
| CL2017001289A1 (es) | Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr). | |
| MX372675B (es) | Anticuerpos anti-jagged1 y metodos de uso. | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| CL2017000654A1 (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
| MY195115A (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
| MX376026B (es) | Inmunoreceptores especificos de claudina-6 y epitopos de celulas t. | |
| LT3183268T (lt) | Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui | |
| ES2796903T8 (es) | Procedimiento de uso de inmunoconjugados anti-CD79b | |
| BR112017009517A2 (pt) | receptores de antígeno quimérico anti-cldn e métodos de uso | |
| CO2017002159A2 (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| MX384989B (es) | Uso de un agonista del receptor x retinoide (rxr) en combinación con una hormona tiroidea para el tratamiento de esclerosis múltiple. | |
| CL2016002008A1 (es) | Proceso para la elaboración de derivados de pirimidin sulfamida. | |
| CL2018003045A1 (es) | Semaglutida en afecciones cardiovasculares. | |
| MX385085B (es) | Uso de beta-agonistas del receptor de la hormona tiroidea. | |
| EA201792312A1 (ru) | Конструкции на основе калихеамицина и способы их применения | |
| EA201790373A1 (ru) | Способы получения модуляторов toll-подобных рецепторов | |
| CA3021677C (en) | USE OF BETA-AGONISTS OF THYROID HORMONES |